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Abstract 
INTRODUCTION: Reduction in hippocampal and amygdala volume measured via structural 
MRI is an early marker of Alzheimer’s disease (AD). Whether genetic risk factors for AD 
exert an effect on these subcortical structures independent of clinical status has not been fully 
investigated.  
METHODS: We examine whether increased genetic risk for AD influences hippocampal and 
amygdala volumes in case-control and population cohorts at different ages, in 1674 Older 
(aged >53yrs; 17% AD, 39% MCI) and 467 young (16-30 yrs) adults.  
RESULTS: An AD polygenic risk score (PRS) combining common risk variants excluding 
APOE, and a SNP in TREM2, were both associated with reduced hippocampal volume in 
healthy older adults and those with mild cognitive impairment (MCI). APOE ε4 was 
associated with hippocampal and amygdala volume in those with AD and MCI, but was not 
associated in healthy older adults.  No associations were found in young adults.   
DISCUSSION: Genetic risk for AD affects the hippocampus before the clinical symptoms of 
AD, reflecting a neurodegenerative effect prior to clinical manifestations in older adults.  
 
Key words 
Alzheimer’s disease; Polygenic risk score; APOE; TREM2; Hippocampus; Amygdala. 
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1. Introduction 
The strongest identified genetic risk factor for Alzheimer’s disease (AD) is the APOE ε4 
allele (Genin, et al., 2011).  Large-scale GWASMA (Genome Wide Association Study Meta 
Analyses) have identified an additional 19 common risk loci with small effects on AD risk 
(Lambert, et al., 2013). A low frequency missense variant in TREM2 (p.R47H or rs75932628) 
substantially increases AD risk (Guerreiro, et al., 2013). Whether these variants exert an 
effect on disease related phenotypes (such as brain atrophy) in the early stages of AD, or 
before clinical onset is largely unknown. 
The earliest histopathological changes in AD are typically seen within the medial temporal 
lobe, where neurofibrillary tangles and amyloid depositions first form. Beginning in the pre-
clinical phase, these lesions lead to changes in regional brain volumes, in particular the 
hippocampus and amygdala (Yang, et al., 2012). Brain volume reduction is evident in other 
disorders (e.g. depression and anxiety) as well as in healthy aging, with the hippocampus 
being especially vulnerable (Small, et al., 2011). Determining how AD risk variants affect 
hippocampal and amygdala volume directly, and whether this is detectable before clinical 
manifestations of AD, will provide clues as to how they contribute to disease risk. 
An effect of APOE status has been observed on structural brain changes in the elderly. 
Carriers of ε4 are generally found to have smaller hippocampal and amygdala volumes than 
homozygous ε3 subjects, but this is not consistently observed before the onset of MCI or AD 
(Hostage, et al., 2013,Khan, et al., 2014,Liu, et al., 2010). Effects have also been identified in 
young people (O'Dwyer, et al., 2012), though findings have also been inconsistent (Khan, et 
al., 2014). In addition, sex differences have been reported, with greater deleterious effect of 
APOE ε4 on hippocampal pathology in females (Fleisher, et al., 2005).  
Other common AD genetic risk factors identified though GWAS studies have been 
investigated in relation to hippocampal and amygdala volume, through the use of polygenic 
5 
 
risk scores (PRS). A PRS allows the identification of phenotypic associations that would not 
be detectable using single variants with low effect size, as well as allowing a reduction in the 
number of statistical tests (Wray, et al., 2014). A PRS containing the first AD GWAS 
findings (three genome-wide associated variants) was found to be associated with clinical 
diagnosis and reduced hippocampal and amygdala volume in the AD case/control cohort 
ADNI (Alzheimer’s Disease Neuroimaging Initiative) (Biffi, et al., 2010). A proxy for the 
rare TREM2 risk variant (rs9394721) was also associated with smaller hippocampal volume 
and increased rate of temporal lobe atrophy in the ADNI cohort (Rajagopalan, et al., 2013).  
 
A recent study assessed the effect of 20 AD risk variants combined in a PRS with various 
MRI markers of brain aging (intra-cranial volume, total brain volume, hippocampal volume, 
white matter hyperintensities and brain infarcts ) in nondemented older community persons 
(Chauhan, et al., 2015). The PRS was applied to meta-analysis summary estimates from ten 
population based studies (total N=11,500). An association was observed with smaller 
hippocampal volume only, which remained significant after excluding APOE. Here we 
extend on this previous work by investigating the effect of AD genetic risk variants on 
hippocampal volume, and also investigate amygdala volume in our large sample (N>2000). 
By accessing the raw genotyping data, as opposed to meta-analysis summary estimates we 
are able to test for an effect in distinct  diagnositic groups, including AD, MCI and healthy 
elderly to examine at which clinical stage effects can be seen. We also tested for any early 
effects of AD risk factors on hippocampal and amygdala volume in healthy young adults 
prior to substantial age related atrophy. Age and sex interaction effects were also 
investigated. We used the most recent GWAS findings identified by the International 
Genomics of Alzheimer’s Project (IGAP) GWASMA which included 74,046 individuals 
(Lambert, et al., 2013) to select the nineteen genome wide significant AD risk variants to 
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include in the PRS. We also examine the effect of several additional PRS adding increasing 
numbers of SNPs at different P value thresholds of association. Inclusion of SNPs that do not 
pass the threshold for genome wide significance, but include a proportion of truly associated 
variants will give increased power to detect an association up to an optimal P value cut-off 
(Wray, et al., 2014).  
 
2. Methods 
2.1 Participants 
Five cohorts, including two case-control and three population based, were used (Table 1. 
ADNI (Mueller, et al., 2005, Alzheimer's Disease Neuroimaging Initiative, www.adni-
info.org) and AddNeuroMed (Westman, et al., 2011, Innovative Medicines (InnoMed) in 
Europe) are comprised of AD cases, MCI, and aged matched controls (Table 1). All AD cases 
met criteria for either probable or definite AD with inclusion criteria as previously described 
(Simmons, et al., 2011 and www.adni-info.org). MCI was assessed as having an abnormal 
memory complaint but with general cognition and functional performance sufficiently 
preserved such that a diagnosis of AD cannot be made. Elderly controls were screened for 
dementia. 
The population cohorts were the Older Australian Twins Study (OATS) (Sachdev, et al., 
2011), the Sydney Memory and Ageing Study (MAS) (Brodaty, et al., 2012), and the 
Queensland Twin Imaging (QTIM) cohort, of which the latter consists of young adults 
(Hibar, et al., 2013). For Sydney MAS and OATS diagnosis of MCI and AD were made with 
the most recent consensus criteria (Winblad, et al., 2004). For all those participants whose 
neuropsychological or functional profiles indicated the possibility of dementia, a diagnosis 
was made at a consensus meeting (for a detailed description of Sydney MAS and OATS 
methodologies see Sachdev, et al., 2009,Sachdev, et al., 2012). Both Sydney MAS and OATS 
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are longitudinal studies; here we utilized the MRI data and diagnosis of MCI or AD at 
baseline (i.e. on admission). 
All cohorts are independent of the IGAP GWASMA except for ADNI, which contributed 
1.6% of the AD cases and 0.5% of the controls (Lambert, et al., 2013). In this study we 
formed an All-Older group, aged 53-91 years, from four cohorts (ADNI, AddNeuroMed, 
OATS and Sydney MAS), and stratified into AD, MCI and Healthy Older groups. The QTIM 
cohort (aged 16-30 years) formed a separate Young Adult group (Table 1). As OATS and 
QTIM cohorts contain twins we omitted related individuals at random. 
 
2.2 Hippocampal and Amygdala volumes 
Subcortical volumes for the hippocampus and amygdala, and intracranial volume (ICV) 
were extracted from anatomical T1-weighted magnetic resonance images (Image acquisition 
is described in Supplementary Methods 1 and Supplementary table 1), using validated 
automated segmentation programs following the ENIGMA (Enhancing Neuro Imaging 
Genetics through Meta-Analysis) Consortium protocols (Stein, et al., 2012). 
 For the ADNI, AddNeuroMed and QTIM samples, bilateral amygdala and hippocampus 
volume segmentation was performed using the Freesurfer image analysis suite, previously 
reported in depth (Fischl, et al., 2002). Briefly, the T1 structural magnetic resonance imaging 
(MRI) scan is corrected for intensity bias, skull stripped, and transformed to Talairach space. 
Each voxel within the MRI volume is then assigned a neuroanatomic label (including left and 
right hippocampus and amygdala) based on probabilistic information estimated from a 
manually labelled training set. ICV was estimated based on the determinant of the 
transformation matrix used when transforming the MR volume to Talairach space.   
FSL FIRST was utilised to segment subcortical structures for the Sydney MAS and OATS 
datasets as previously reported (Patenaude, et al., 2011). Input images were registered to MNI 
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space through two-stage linear transformation. Deformable mesh models, based on shape and 
intensity information from a manually segmented training set, were then used to segment 
bilateral hippocampus and amygdala volumes. ICV was calculated as the inverse of the 
determinant of the affine transformation matrix, multiplied by the size of the MNI template. 
We calculated the mean of left and right hippocampal volume and amygdala volume. All 
subcortical volumes and ICV (intracranial volumes) outliers were winsorised to 4 standard 
deviations from the mean. 
 
2.3 Genetic data 
A polygenic risk score (PRS) was constructed from genome-wide SNP array data using 19 
genome wide significant AD risk variants (from IGAP, PRS P<5x10-8) (Lambert, et al., 
2013). Scores were calculated by summing the number of risk alleles weighted by the effect 
size (log odds ratio) (Supplementary Table 2).  
Threshold PRS were calculated with stage 1 summary data from IGAP using the method 
previously described (Purcell, et al., 2009) (see Supplementary Methods 3 for details of the 
IGAP discovery sample). SNPs within 500kb either side of the APOE locus were excluded to 
ensure all APOE associated signal was removed. LD-based clumping was carried out on all 
SNPs in the summary data, providing the most significantly associated SNP in each region of 
LD (using PLINK clumping command with a pairwise r2 threshold of 0.2 and a physical 
distance threshold of 300kb). SNPs were checked for flip strands between the summary data 
and each cohort. We calculated the total score for each individual as the number of score 
alleles weighted by the log of the odds ratio from the discovery SNPs from the IGAP sample 
(using PLINK score function). The risk score calculation was repeated for P value thresholds 
of P<1x10-6, P<1x10-4, P<1x10-3, P<0.01, P<0.05, P<0.1, P<0.5 and P<1 (all SNPs). The 
number of SNPs included in each risk score is shown in Supplementary Table 3.  
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The PRS method assumes a polygenic disease model and is suitable for common variants 
with the assumptions of an additive effect and independent contribution to risk (Wray, et al., 
2014). Both APOE and TREM2 don’t meet these assumptions and were assessed separately 
from the PRS. APOE ε4 allele is a diplotype acting under a co-dominant genetic model, and 
with a much larger effect size than the other common AD risk variants (Genin, et al., 2011). 
For the rare TREM2 variant (p.R47H/rs75932628) we used rs9394721, the closest available 
imputed proxy (r2=0.492) (Rajagopalan, et al., 2013).  APOE genotyping was carried out as 
previously described (Jorm, et al., 2007). Haplotype ε2/ε4 carriers were excluded from the 
analysis due to the potential for counteracting effects of these alleles (1.7% of individuals). 
 
2.4 Statistical Analyses 
To assess how well the PRS predicted AD risk, we first tested for an association of each 
PRS with clinical status (excluding MCI) in the AddNeuroMed cohort which is independent 
from the IGAP discovery sample, using logistic regression (STATA version 11), controlling 
for age, sex and 4 ancestry principal components. Discriminative improvement of each PRS 
was assessed using receiver operating characteristic (ROC) curves. The equality of each area 
under the curve (AUC) for the ROC curves were testing using STAT “roccomp” taking into 
account the implicit correlation between curves (as the test is applied to the same sample). A 
covariance matrix is estimated using the method of structural components and the resulting test 
statistic has an asymptotically χ2 distribution (DeLong, et al., 1988). We also tested the 
association between both the APOE e4 genotype and the TREM2 SNP and AD risk. 
 
Next in each of the five cohorts we tested for an effect of PRS, the number of TREM2 
rs9394721 and APOE ε4 alleles on mean hippocampal and amygdala volumes, using linear 
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regression. Covariates included ICV, age, sex, and four ancestry principal components. Age2, 
age*sex, age2*sex were also included as covariates if they showed evidence of an association 
(P<0.05).  
We then combined all cohorts in a mega-analysis to test for associations in the All-Older 
group (a combined dataset incorporating the AD, MCI and Healthy Older groups shown in 
table 1), controlling for study and clinical status as well as stratifying by clinical status (AD, 
MCI and Healthy Older). Where there was a significant association we repeated the analyses 
testing for interaction effects of both sex and age, by including an interaction term for both 
sex and age with the independent variable (either number of APOE ε4 alleles, TREM2 
rs9394721 alleles and PRS) in the regression equation. Non-significant product terms were 
removed and the regression repeated. Interactions were identified by a significant product 
term and the nature of the interaction was investigated by testing the association in separate 
age and gender groups.  
For all regression analysis the variance explained (R2) was calculated by taking the R2 
value of the full model (covariates and genotype/PRS) and subtracting the R2 of the reduced 
model (covariates only). We also assessed the total variance explained by all the investigated 
AD risk variants by including PRS P<1x10-4, APOE ε4 and TREM2 together within a single 
multiple regression and again subtracting the R2 of the reduced model (covariates only) from 
the total R2. 
Due to ascertainment and measurement differences between cohorts we also carried out a 
meta-analysis (STATA METAN specifying a random effects model) and tested for study 
heterogeneity. Meta-analyses tested for an association between the number of APOE ε4 
alleles, the PRS P<0.001 and TREM2 rs9394721, with hippocampal volume and amygdala in 
the combined All-Older group (controlling for disease status), AD, MCI and Healthy Older 
groups. 
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3. Results 
3.1 AD risk 
The AD PRS was associated with AD risk in the AddNeuroMed cohort. The most 
significantly associated threshold was P<1x10-3 (OR=1.51; P=0.011), though this had no 
more discriminative accuracy than a model with only age and sex covariates. However APOE 
ε4 genotype was highly associated with AD risk (OR=2.41 p=1.64x10-5) with significant 
improvement in discriminative accuracy over the covariates. In contrast TREM2 rs9394721 
was not associated with AD risk in this small sample (Table 2). 
 
3.2 Hippocampal and amygdala volume 
The effects of PRS, TREM2 and APOE on hippocampal and amygdala volume in the 
mega-analysis are shown in Tables 3 and 4 and Figure 1, with Table 3 showing results for the 
combined All-Older and the young adults, and Table 4 stratifying the older group by clinical 
group (AD, MCI, Healthy Older). Results from each of the four older cohorts when analysed 
separately are presented in Supplementary Table 4. 
APOE ε4 status was strongly associated with lower hippocampal and amygdala volumes in 
the All-Older group. However, when stratified by clinical status, APOE ε4 associated with 
lower volumes in the AD and MCI groups, but not in the Healthy Older group.  In the AD 
group, this constitutes each APOE ε4 allele resulting in an average of 143 mm3 (4.8%) 
reduction in mean hippocampal volume and 47 mm3 in mean amygdala volume (3.8%). For 
MCI this was a 132 mm3 reduction in hippocampal volume (4.0%), and 37mm3 in amygdala 
volume (2.8%). No associations were found in the Young Adults.  
We also found an association of PRS containing common AD risk variants of small effect 
with reduced hippocampal volume in the All-Older group. The strongest effect was for the 
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PRS containing SNPs below the P<10-4 threshold (p=0.004). This association was suggestive 
in the stratified MCI (N=645 PRS P<1x10-4 p=0.057) and Healthy Older (N=723 PRS 
P<1x10-3 p=0.075) sub-groups, but not apparent in the smaller AD group. In the Young 
Adults there was no effect of the PRS on hippocampal volume, and no effect of PRS was 
identified for amygdala volume in any group.  
TREM2 rs9394721 was associated with lower hippocampal volume in the All-Older 
group. It showed suggestive association in the MCI and Healthy Older groups (significant 
when not corrected for multiple testing), but not in the smaller AD group or Young Adults. 
No association was found between TREM2 and amygdala volume.  
The variance explained (R2) by APOE ε4, PRS and TREM2 rs9394721 on hippocampal 
and amygdala volume are shown for each regression in tables 4-5, and for hippocampal 
volume in figure 1. When we assessed the variance explained by all the genetic risk factors 
combined (by including APOE ε4, PRS P<1e04 and TREM2 rs9394721 within a single 
multiple regression) on hippocampal volume we found that they accounted for an R2 of 1.6% 
in the All-Older group, 3%  in the AD group, 3.2% in the MCI group and 0.3% in the Healthy 
Older group. 
Age and sex interactions were identified and are shown as footnotes in Tables 3 and 4. The 
APOE effect was stronger in females (in the All-Older group N=817, β=-0.15, p=3.4x10-8), 
with an interaction found between APOE ε4 and sex in both AD and MCI groups. There was 
also an interaction between PRS (testing threshold P<1x10-3) and sex, where the effect was 
again driven by the females (in the All-Older group: N=848, β=-0.08, p=0.001). For TREM2 
we identified an age*rs9394721 interaction in the All-Older group, with an association found 
for those ≤75 years (N=791, β=-0.10, P=3.4x10-4) but not >75 years, and no frequency 
difference between the two age groups. When stratified by clinical status the age effect was 
only evident in the MCI group (≤75 years: N=292, β=-0.19, P=0.003). 
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The results for the meta-analysis are shown in Supplementary table 5 and Supplementary 
Figures 1-3).  The association of APOE ε4 genotype and hippocampal volume in MCI and 
AD was confirmed but the association between APOE ε4 and amygdala volume was not 
significant in the meta-analysis, likely due to heterogeneity across studies in the measurement 
of this structure. The association of TREM2 rs9394721 was confirmed in the All-Older group, 
but was not significant in any of the clinical groups. Similarly, the association between PRS 
and hippocampal volume was not significant, reflecting the small effect and loss of power 
due to the meta analysis.  
 
4. Discussion 
Chauhan et al. (2015) recently showed that an AD PRS constructed from 20 AD risk loci 
associated with reduced hippocampal volume in a large population based meta-analysis. Here 
we confirm these findings using raw genotype level data using a smaller sample size, but 
including a larger number of variants in the PRS identified in the largest GWASMA available 
(IGAP discovery sample: 17,008 cases, 37,154 controls (Lambert, et al., 2013)). We also 
investigate a variant in TREM2. Through stratification into AD, MCI and healthy older 
groups, we show at which disease stage associations can be identified.   
In our cross-study mega-analyses we confirm the association between APOE and 
hippocampal volume in adults with Alzheimer’s disease and mild cognitive impairment 
(MCI) (ε4 carriers having smaller volumes compared to non-carriers), but show no 
association in healthy older adults or in young adults.  The same pattern of association, 
although to a lesser degree, was found for amygdala volume. In addition, AD polygenic risk 
scores (PRS, excluding APOE) and the rare variant TREM2 were also found to be associated 
with hippocampal volume in older adults (i.e. All-Older group). The AD PRS association was 
driven by females, while the TREM2 association was limited to those aged 75 years and 
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under, and both appear associated with volume loss during healthy aging and in cases of 
MCI. Notably, the PRS explain substantially less of the variance in hippocampal volume than 
APOE genotype, Nevertheless, In the AD and MCI cohorts, the combined effects of APOE 
ε4, the AD risk score, and TREM2 accounted for more variance in hippocampal volume than 
APOE ε4 alone (fig 1). Combining the effects of the AD genetic risk variants (i.e. APOE, AD 
PRS, and TREM2), increases the total variance in hippocampal volume that can be explained 
in AD (to 3%) and in those with MCI (to 3.2%).  However, in the healthy elderly TREM2 is a 
better predictor alone (accounting for 0.3% of variance in hippocampal volume). 
Longitudinal studies exploring healthy aging and transition to MCI and AD will provide 
further clarity regarding these genetic profiles.  
In contrast to the mega-analysis findings, meta-analyses only confirmed the strong 
association between APOE and hippocampal volume, and the TREM2 rs9394721 in the larger 
combined All-older group. The reduction in significance in the groups with small sample 
sizes likely reflects heterogeneity across studies, and highlights the additional insights to be 
gained from mega-analyses. 
The differing effects of AD risk variants at different disease stages may give insight into 
the mechanisms of how they contribute to AD risk. Shared mechanisms may drive brain 
aging and AD, with clinical onset resulting when brain aging surpasses a threshold 
(Swerdlow, 2011). Support for this hypothesis comes from gene expression studies that 
identify substantial overlap between expression changes with age, and in AD (Avramopoulos, 
et al., 2011). An opposing view is that volume differences associated with AD risk may be 
identifiable before clinical diagnosis because they are prodromal changes. Amyloid 
deposition and the specific pattern and acceleration of atrophy in AD compared to normal 
aging suggests that early AD is different from normal aging (Fjell, et al., 2014). Recent 
findings suggest that AD related hippocampal atrophy can be detected 4.2 years prior to onset 
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of clinical manifestations of dementia (Villemagne, et al., 2013). Testing the effect of these 
variants in middle age is the important next step in ascertaining how early the AD risk variant 
effect on degeneration can be identified.  We found no association in young adulthood, 
although in a sub-sample of the same cohort previous work has found an association between 
the CLU genotype and white matter microstructure (Braskie, et al., 2011), suggesting other 
MRI measures may be more sensitive to early differences. This could include examination of 
the hippocampal microstructure, such as CA1 and subiculum regions, as patterns in volume 
reductions in subfields of the hippocampus together with entorhinal cortex may differentiate 
between AD and healthy aging (Wisse, et al., 2014).  
We show that AD variants below genome wide significance contribute to the variance in 
hippocampal volume. The PRS containing SNPs below the P<10-4 threshold was the most 
highly associated with AD disease status and with hippocampal volume in older adults. The 
threshold that maximises the variance explained in the target sample depends on the size of 
the GWASMA discovery sample and the underlying genetic architecture (Wray, et al., 2014).  
Notably, in preliminary analyses we did not identify any association with PRS and 
hippocampal volume when using data from an earlier AD GWASMA with a smaller sample 
size (GERAD discovery sample: 3,941 cases, 7,848 controls (Harold, et al., 2009); data not 
shown). Large scale studies also using the GERAD discovery sample have found no 
association of AD PRS without APOE with memory or cognitive ability in people without 
dementia (Harris, et al., 2014,Verhaaren, et al., 2013). In light of our results these should now 
be tested using the latest IGAP GWASMA.  
Our finding that PRS has a stronger effect on hippocampal volume in females adds to the 
literature showing the importance of taking sex into account in genetic association analysis in 
AD. The stratification of AD GWASMA by sex would be useful, allowing the generation of 
sex specific PRS (Altmann, et al., 2014,Azad, et al., 2007). All cohorts in the discovery 
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sample had excess females (58-68%) (Lambert, et al., 2013), so the PRS may be biased 
towards female genetic risk factors.  
TREM2 is a receptor expressed on microglia that stimulates phagocytosis of cell debris 
and suppresses inflammatory reactivity. Over expression in the brains of AD transgenic mice 
ameliorates Aβ deposition, neuroinflammation, and neuronal loss (T. Jiang, et al., 2014). 
Thus, in humans, mutation carriers may have an inflammatory phenotype with impaired 
tissue debris clearance resulting in increased grey matter atrophy during aging. We build on 
the previous finding of an association of rs9394721, a R47H proxy with hippocampal volume 
in ADNI (Rajagopalan, et al., 2013), and show that the association is independent of clinical 
status and evidence of an association is detectable before onset of MCI. Indeed, we found 
associations to be limited to the Healthy Older adult and MCI groups, and the effect to be 
stronger in those aged  ≤75 years. Previously the R47H genotype has been associated with 
lower cognitive function in those without AD and has been shown to confer increased risk for 
Parkinson’s disease, frontotemporal dementia and amyotrophic lateral sclerosis (Jonsson, et 
al., 2013,Yaghmoor, et al., 2014). As rs9394721 is a  relatively poor proxy for the disease 
causing variant (r2=0.492) (Rajagopalan, et al., 2013), it is likely that a stronger association 
would be identified if direct genotyping results were available. 
We did not find any association of PRS, or TREM2 on amygdala volume, contrary to the 
association of PRS and amygdala volume reported in the ADNI case-control cohort (Biffi, et 
al., 2010). Amygdala volume is significantly reduced in AD in a similar magnitude to the 
hippocampus (Klein-Koerkamp, et al., 2014). However, we have previously shown that 
amygdala atrophy is not identified over a two year follow-up period in elderly population 
samples, which contrasts with significant atrophy in the hippocampus (J. Jiang, et al., 2014). 
Less age related atrophy in the amygdala and potential unreliably of segmentation of this 
small structure may reduce power to detect an effect.  
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APOE ε4 was associated with lower hippocampal and amygdala volumes in the combined 
All-Older group, with a large effect in those with AD and MCI (≥4% average difference in 
hippocampus and ≥2.8% in amygdala per APOE ε4 allele). The association is stronger in 
females, as previously shown in those with MCI (Fleisher, et al., 2005). An increasing body 
of work shows an interaction between APOE and sex in AD risk which may be explained by 
the influence of estrogen levels acting in concert with APOE (Altmann, et al., 2014,Stone, et 
al., 1997). APOE ε4 was not associated with hippocampal volume in Healthy Older 
conflicting with some previous reports (Biffi, et al., 2010,Lind, et al., 2006,Reiman, et al., 
1998,Wishart, et al., 2006) but in agreement with recent findings from other large scale 
studies, including both measures of volume and atrophy (Ferencz, et al., 2013,Manning, et 
al., 2014). Population studies of older people are likely to have a proportion of individuals 
with MCI, which may be the source of identified APOE association in conflicting reports.  
Even so, an effect in the healthy elderly may be detectable in a larger sample, especially as 
there is a reduced frequency of APOE ε4 alleles compared to AD and MCI groups. In 
cognitively healthy adults a large scale meta analysis showed that APOE ε4 carriers 
performed worse on measures of episodic memory, and global cognitive ability, with effect 
sizes increasing as age increases (Wisdom, et al., 2011). There are also conflicting reports on 
the effect of APOE on hippocampal volume in young people (Khan, et al., 2014,O'Dwyer, et 
al., 2012). In agreement with our result, a large study (N=1400) of 14 year olds also found no 
association (Khan, et al., 2014).  Recent evidence of neurodevelopmental effects of APOE 
have been identified as affecting grey matter volumes in infants and neonates, suggesting that 
associations may be transient and could be clearer at a very young age (Dean, et al., 
2014,Knickmeyer, et al., 2014).  
In summary, in addition to the APOE4 genotype, a PRS comprised of common AD risk 
variants of small effect, and TREM2 associate with hippocampal volume independently of 
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clinical status in the elderly. TREM2 is associated in Healthy Older and MCI individuals, 
with the AD PRS showing a trend nearing significance. This correlation with early MRI 
markers of AD shows evidence for a genetic modulation of neurodegeneration, and the 
potential for a combination of PRS and brain biomarkers to aid in the prediction of future 
cognitive decline and the development of AD.   
A limitation of this study is in the combining of results across several cohorts with 
participant ascertainment and diagnostic adjudication as well as the use of multiple scanner 
platforms adding variability in the volumetric measures used. This is reflected as significant 
between study heterogeneity when the analysis is performed as a meta-analysis 
(Supplementary table 5). Replication in independent samples is required to confirm these 
findings, and testing the effect of these variants in middle age is the important next step to 
ascertain how early the prodromal AD risk variant effects on degeneration can be identified.   
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Table 1. Demographics and descriptive statistics for (A) The five cohorts and (B) the derived AD, MCI, and Healthy Older and Young Adult 
groups. 
A. Cohort N (% Male ) 
Mean Age 
(SD, range) 
% AD, MCI APOE ε4 Frequency*(N) 
Mean Hippocampal 
Volume mm3 (SD)† 
Mean Amygdala 
Volume mm3 (SD)† 
ADNI 741 (59.9) 75.5 (6.8,55-91) 23.3, 48.7 0.300 (741) 3397 (574) 1488 (273) 
AddNeuroMed 356 (43.5) 74.4 (6.1,53-89) 33.7, 32.0 0.254 (293) 3098 (613) 1176 (259) 
Sydney MAS 542 (45.4)  78.4 (4.7,70-90) 0, 32.3 0.123 (534) 3371 (422) 1109 (248) 
OATS 199 (32.7) 70.3 (5.2,65-89) 0.5, 12.7 0.169 (186) 3600 (436) 1195 (205) 
QTIM 467 (37.9) 22.9 (3.3,16-30) 0,0 0.137 (417) 4095 (393) 1673 (239) 
B, Group N (% Male ) 
Mean Age 
(SD, range) 
 
APOE ε4 Frequency*(N) 
Mean Hippocampal 
Volume mm3 (SD)† 
Mean Amygdala 
Volume mm3 (SD)† 
AD 280 (49.6) 75.5 (7.1, 55-91) 
 
0.403 (267) 2933 (586) 1233 (328) 
MCI 648 (56.8) 75.8 (6.7, 55-88) 
 
0.264 (624) 3312 (522) 1336 (314) 
Healthy Older 746 (42.2) 75.3 (5.9, 53-90) 
 
0.138 (735) 3553 (453) 1291 (299) 
Young Adults 467 (37.9) 22.9 (3.3,16-30) 
 
0.137 (417)  4095 (393) 1673 (239) 
AD, MCI and Healthy Older groups are comprised from ADNI and AddNeuroMed case/control cohorts and Sydney MAS and OATS population based cohorts. 
All-Older group incorporates the AD, MCI and Healthy Older groups, Young Adults are from QTIM.  
*APOE genotyping and GWAS were not available for all subjects.  
†Not corrected for ICV, sex, or age. 
Abbreviations: SD, standard deviation; ICV, intracranial volume; AD, Alzheimer’s disease; MCI, mild cognitive impairment; APOE, Apolipoprotein E; ADNI, 
Alzheimer’s Disease Neuroimaging Initiative; Sydney MAS, Sydney Memory and Ageing Study; OATS, Older Australian Twins Study; QTIM, Queensland 
Twin Imaging. 
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Table 2. Association between AD Polygenic Risk Scores (PRS) and disease status (AD vs 
Control) in AddNeuroMed. 
 N OR SE P Pseudo R2 * AUC † 
APOE ε4 188 2.41 0.49 1.64x10-5 0.086 0.800 
PRS P<1 202 1.19 0.19 0.280 0.004 0.725 
PRS P<0.5 202 1.18 0.19 0.318 0.004 0.727 
PRS P<0.1 202 1.06 0.17 0.696 0.001 0.724 
PRS P<0.05 202 1.07 0.17 0.657 0.001 0.724 
PRS P<0.01 202 1.14 0.18 0.410 0.003 0.727 
PRS P<1x10-3 202 1.41 0.23 0.032 0.017 0.734 
PRS P<1x10-4 202 1.51 0.24 0.011 0.024 0.745 
PRS P<1x10-6 202 1.37 0.22 0.040 0.016 0.737 
PRS P<5x10-8 202 1.45 0.23 0.020 0.021 0.739 
TREM2 rs9394721 202 0.96 0.14 0.784 0.000 0.722 
 
APOE and GWAS data were not available for all subjects, and individuals with ε2/ε4 genotype were 
excluded for analysis including APOE genotype. The ratio of AD to controls is 1.05:1. 
Abbreviations: APOE, Apolipoprotein E; N, number; OR, odds ratio; SE, standard error. AUC; Area 
under the ROC curves, 
*The Pseudo R2 is the McFadden’s R2 and is an estimation of the proportion of variance explained by 
the predictor. 
†The AUC of the regression equation with covariates only (age, sex and 4 ancestry principle 
components have) is 0.721, with the APOE ε4 being the only variable which increases the AUC above 
using covariates alone at level which is statically significant (χ2=1.62 p=0.014) . 
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Table 3. Mega-analysis of the effect of AD genetic risk factors on hippocampal and amygdala volume 
in Older and Young Adults. 
 
  Mean Hippocampus Mean Amygdala 
  N R2 β (SE)   P N R2 β (SE)   P 
All-Older APOE ε4 1611 0.011 -0.11 (0.02) 8.7x10-9 a 1607 0.003 -0.05 (0.02) 0.004 
 PRS P<5x10-8 1664 0.000 -0.02 (0.02) 0.229 1660 0.000 0.02  (0.02) 0.381 
 PRS P<1x10-6 1664 0.002 -0.04 (0.02) 0.030 1660 0.000 -0.01 (0.02) 0.607 
 PRS P<1x10-4 1664 0.003 -0.05 (0.02) 0.004 1660 0.000 -0.01 (0.02) 0.746 
 PRS P<1x10-3 1664 0.002 -0.05 (0.02) 0.007b 1660 0.000 0.01  (0.02) 0.633 
 PRS P<0.01 1664 0.000 -0.02 (0.02) 0.246 1660 0.000 0.00  (0.02) 0.919 
 PRS P<0.05 1664 0.000 -0.02 (0.02) 0.315 1660 0.000 0.00  (0.02) 0.819 
 PRS P<0.1 1664 0.000 -0.02 (0.02) 0.369 1660 0.000 0.01  (0.02) 0.793 
 PRS P<0.5 1664 0.000 -0.01 (0.02) 0.480 1660 0.000 0.01  (0.02) 0.580 
 PRS P<1 1664 0.000 -0.01 (0.02) 0.663 1660 0.000 0.01  (0.02) 0.725 
 TREM2 rs9394721 1664 0.004 -0.06 (0.02) 0.001c 1660 0.000 -0.02 (0.02) 0.389 
Young 
Adults  
APOE ε4 401 0.000 0.02  (0.04) 0.653 404 0.006 -0.08 (0.05) 0.120 
PRS P<5x10-8 447 0.004 -0.06 (0.04) 0.126 450 0.006 -0.08 (0.05) 0.091 
 PRS P<1x10-6 447 0.000 0.01  (0.04) 0.801 450 0.000 0.02  (0.05) 0.656 
 PRS P<1x10-4 447 0.002 -0.04 (0.04) 0.291 450 0.001 0.03  (0.05) 0.522 
 PRS P<1x10-3 447 0.004 -0.06 (0.04) 0.111 450 0.000 0.02  (0.05) 0.734 
 PRS P<0.01 447 0.000 -0.02 (0.04) 0.646 450 0.001 0.03  (0.05) 0.468 
 PRS P<0.05 447 0.001 0.02  (0.04) 0.562 450 0.002 0.04  (0.05) 0.351 
 PRS P<0.1 447 0.000 0.02  (0.04) 0.651 450 0.002 0.04  (0.05) 0.395 
 PRS P<0.5 447 0.000 0.00  (0.04) 0.972 450 0.000 -0.02 (0.05) 0.687 
 PRS P<1 447 0.000 0.00  (0.04) 0.996 450 0.000 -0.02 (0.05) 0.690 
 TREM2 rs9394721 447 0.000 0.00 (0.04) 0.991 450 0.000 0.00  (0.05) 0.921 
 
The combined All-Older group comprises the four elderly cohorts (ADNI, AddNeuroMed, OATS and 
Sydney MAS, including those with AD, MCI and Healthy Older). Cohort and disease status included 
as covariates along with standard covariates.  The Young Adult group comprises the QTIM cohort. 
Significant associations are shown in bold. 
aStronger association in females (N=817 β=-0.15 p=3.4x10-8) compared to males (N=794 β=-0.08 
p=0.004). 
bAssociation driven by females (Females; N=848, β=-0.08, p=0.001 and Males; N=816, β=-0.01, 
p=0.626). 
cAssociation found in those 75 years of age or younger (≤75 years: N=791, β=-0.10, P=3.4x10-4 ;  >75 
years; N=873, β=0.028, P=0.240). 
Abbreviations: R2, the variance explained by the genotype/PRS; β, standardised Beta; SE, standard 
error;  
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Table 4. Mega analysis of the effect of AD genetic risk factors on hippocampal and amygdala volume 
in the AD, MCI and Healthy Older groups. 
 
  Mean Hippocampus Mean Amygdala 
  N R2 β (SE)   P N R2 β (SE)   P 
AD APOE ε4 267 0.027 -0.18 (0.04) 1.1 x10-4 a 268 0.008 -0.11 (0.05) 0.023 
 PRS P<5x10-8 279 0.000 0.00  (0.04) 0.951 280 0.000 -0.01 (0.05) 0.760 
 PRS P<1x10-6 279 0.000 0.00  (0.04) 0.932 280 0.007 -0.09 (0.05) 0.053 
 PRS P<1x10-4 279 0.000 -0.02 (0.05) 0.655 280 0.001 -0.03 (0.05) 0.512 
 PRS P<1x10-3 279 0.001 -0.03 (0.04) 0.442 280 0.000 -0.02 (0.05) 0.718 
 PRS P<0.01 279 0.001 -0.02 (0.04) 0.600 280 0.000 -0.02 (0.05) 0.705 
 PRS P<0.05 279 0.000 -0.01 (0.04) 0.780 280 0.000 0.01  (0.05) 0.860 
 PRS P<0.1 279 0.000 -0.01 (0.04) 0.781 280 0.000 0.01  (0.05) 0.825 
 PRS P<0.5 279 0.000 0.00  (0.04) 0.974 280 0.002 0.05  (0.05) 0.278 
 PRS P<1 279 0.000 0.01  (0.04) 0.888 280 0.002 0.05  (0.05) 0.281 
 TREM2 rs9394721 279 0.004 -0.06 (0.04) 0.166 280 0.000 0.01  (0.04) 0.854 
MCI APOE ε4 621 0.024 -0.16 (0.03) 1.5x10-6 b 619 0.005 -0.08 (0.03) 0.012 
 PRS P<5x10-8 645 0.000 -0.02 (0.03) 0.649 643 0.000 0.02  (0.03) 0.511 
 PRS P<1x10-6 645 0.003 -0.05 (0.03) 0.121 643 0.000 0.00  (0.03) 0.910 
 PRS P<1x10-4 645 0.004 -0.07 (0.03) 0.057 643 0.001 0.03  (0.03) 0.361 
 PRS P<1x10-3 645 0.002 -0.04 (0.03) 0.192 643 0.000 0.01  (0.03) 0.674 
 PRS P<0.01 645 0.000 0.01  (0.03) 0.687 643 0.000 -0.01 (0.03) 0.655 
 PRS P<0.05 645 0.000 0.02  (0.03) 0.572 643 0.000 -0.02 (0.03) 0.518 
 PRS P<0.1 645 0.000 0.01  (0.04) 0.825 643 0.001 -0.04 (0.03) 0.248 
 PRS P<0.5 645 0.000 0.01  (0.03) 0.761 643 0.000 -0.02 (0.03) 0.612 
 PRS P<1 645 0.000 0.01  (0.03) 0.716 643 0.000 -0.02 (0.03) 0.607 
 TREM2 rs9394721 645 0.004 -0.06 (0.03) 0.047c 643 0.000 0.00  (0.03) 0.916 
Healthy  APOE ε4 723 0.000 0.00  (0.03) 0.961 720 0.000 -0.01 (0.03) 0.775 
Older PRS P<5x10-8 740 0.002 -0.05 (0.03) 0.157 737 0.001 0.02  (0.03) 0.388 
 PRS P<1x10-6 740 0.001 -0.04 (0.03) 0.289 737 0.000 0.02  (0.03) 0.552 
 PRS P<1x10-4 740 0.002 -0.05 (0.03) 0.126 737 0.001 -0.03 (0.03) 0.298 
 PRS P<1x10-3 740 0.003 -0.05 (0.03) 0.075 737 0.000 0.02  (0.03) 0.503 
 PRS P<0.01 740 0.001 -0.03 (0.03) 0.331 737 0.000 0.01  (0.03) 0.599 
 PRS P<0.05 740 0.001 -0.04 (0.03)  0.228 737 0.001 0.03  (0.03) 0.276 
 PRS P<0.1 740 0.001 -0.03 (0.03) 0.416 737 0.001 0.03  (0.03) 0.208 
 PRS P<0.5 740 0.001 -0.03 (0.03) 0.363 737 0.000 0.01  (0.03) 0.663 
 PRS P<1 740 0.000 -0.02 (0.03) 0.490 737 0.000 0.00  (0.03) 0.910 
 TREM2 rs9394721 740 0.004 -0.06 (0.03) 0.042 737 0.001 -0.04 (0.03) 0.165 
 
The AD group includes AD cases from ADNI and AddNeuromed, the MCI groups includes those with 
MCI from ADNI, AddNeuroMed, Sydney MAS and OATS, and Healthy Older includes healthy controls 
from ADNI and AddNeuroMed, and those with no diagnosis of MCI or dementia from Sydney MAS 
and OATS. P values are not correct for multiple testing. Associations with P<0.05 are shown in bold 
aStronger association in females (N=130, β=-0.27, p=7.3x10-5) compared to males (N=137, β=0.11, 
p=0.068). 
bStronger association in females (N=267, β=-0.21, p=1.7x10-4) compared to males (N=816, β=-0.01, 
p=0.626). 
c Association found in those 75 years of age or younger (≤75 years; N=292, β=-0.19, P=0.003 and 
N=353, β=0.015, P=0.699). 
Abbreviations: R2, the variance explained by the genotype 
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Figure Legends 
Fig 1. Variance explained (R2) by the effect of APOE ε4, PRS and TREM2 rs9394721 on 
hippocampal volume in the Combined All-Older, and in separate clinical groups.  
The combined variance explained (R2) by APOE ε4, PRS P<1e04 and TREM2 rs9394721 within a 
single multiple regression (representing all the variance explained by the AD risk variants 
investigated) totalled 0.016 in the All-Older group. For the separate clinical groups R2= 0.030 in the 
AD group, 0,032 in the MCI group and 0.003 in the Healthy Older group.  
Ns represent the total N of the slightly differing sample sizes for each variant/score (each individual 
sample size is shown in tables 3 and 4)*P<0.05, **P<0.001 represent significant P values for the 
association of the variant/score with hippocampal volume (not corrected for multiple testing).  
   
 
 
 
